The Federal Pain Research Strategy is an effort of the Interagency Pain Research Coordinating Committee and the Office of Pain Policy of the National Institutes of Health to oversee development of a long-term strategic plan for those federal agencies and departments that support pain research. A diverse and balanced group of scientific experts, patient advocates, and federal representatives identified and prioritized research recommendations as a basis for this long-term strategic plan to coordinate and advance the federal pain research agenda. The key areas of prevention of acute and chronic pain, acute pain and acute pain management, the transition from acute to chronic pain, chronic pain and chronic pain management, and disparities in pain and pain care provided the framework for development of the strategy. In addition, a set of cross-cutting research priorities were identified by the task force in topic areas for which similar research recommendations were developed across multiples work groups and merged.
Friday, May 26, 2017
Saturday, May 20, 2017
The research adds to evidence that it's hard for some people to stop taking the pills even after a brief use. State officials in New Jersey recently enacted a law limiting first-time prescriptions to a five-day supply, and other states should consider similar restrictions, says Kit Delgado, an assistant professor of Emergency Medicine and Epidemiology at the University of Pennsylvania.
"The bottom line is that we need to do our best not to expose people to opioids," Delgado says. "And if we do, start with the smallest quantity possible." The research was presented May 17 at the Society for Academic Emergency Medicine's annual meeting in Orlando.
Previous research has found that the more opioids such as hydrocodone and oxycodone are prescribed, the more likely patients are to keep taking them. But previous studies have been too broad to account for differences in diagnoses — for instance, whether people who received refills kept taking the drug simply because they still were in pain, Delgado says. He and colleagues limited their study to prescriptions written after ankle sprains to people who had not used an opioid in the previous six months. Usually, those injuries aren't serious and don't require opioids.
About 7 percent of 53,222 people who visited ERs with ankle sprains in 2011 and 2012 were sent home with an opioid prescription, the researchers found. Patients' experiences varied by state: Less than 2 percent treated in Delaware were prescribed an opioid compared with 16 percent in Mississippi.
The number of pills obtained within a week of those visits also varied greatly, from as few as five to more than 60. Typical prescriptions were for 15 to 40 pills. Those who received prescriptions for 30 pills or more were twice as likely to get refills as those with prescriptions for 15 or fewer, Delgado and colleagues found.
"Because these are patients who have a uniformly minor injury, it emphasizes how much arbitrariness there is in how physicians prescribe opioids," says Michael Barnett, an emergency physician at Brigham and Women's Hospital in Boston, who was not involved in the study.
Saturday, May 13, 2017
Pain in Animals Workshop 2017 – Creating a Research Roadmap for measuring chronic pain in dogs and cats
In parallel, translational success has come under the spotlight. Numerous reviews have highlighted a lack of translation of basic research into new approved therapeutics for treatment of persistent pain in humans. The use of spontaneous painful disease in companion animals has been highlighted as one of the changes that could be made to help improve translation of basic science to new therapeutics, acting as a bridge between preclinical and clinical studies, with the goal of reducing the failure rates of human clinical trials, thus accelerating the approval of new therapeutics. Aspects that will undermine the utility of the 'spontaneous disease pain' model are the lack of valid outcome measures and the lack of knowledge of opportunities.
Wednesday, May 10, 2017
The ACTTION–APS–AAPM Pain Taxonomy (AAAPT) Multidimensional Approach to Classifying Acute Pain Conditions - The Journal of Pain
Tuesday, May 02, 2017
The opioid epidemic could be cured with virtual-reality worlds that let patients escape their pain — Quartz
Judy explains that she suffers from constant, debilitating pain: arthritis, back problems, fibromyalgia and daily migraines. She was a manager at a major electronics company until 2008, but can no longer work. She often hurts too much even to make it out of bed.
She's taking around 20 different medications each day, including painkillers, antidepressants, sedatives and a skin patch containing a high dose of the opioid drug fentanyl, which she says did not significantly help her pain and which she's now trying to come off. Her physician has been tapering the dose for months, so in addition to her pain she suffers withdrawal symptoms: the chills and crawling dread. Then her clinic announced that it would no longer prescribe any opioids at all, the unintended result of new, stricter measures aimed at clamping down on opioid abuse. Faced with losing access to the drug on which she is physically dependent, she has come to another clinic, Pain Consultants of East Tennessee (PCET) in Knoxville, desperate for help.
Saturday, April 22, 2017
Steven Pete has no idea how you feel. Sitting in Cassava, a café in Longview, Washington, next to a bulletin board crammed with flyers and promises—your pain-free tomorrow starts today; remember: you're not alone in your battle against peripheral neuropathy!—he tells me he cannot fathom aches or pinches or the searing scourge of peripheral neuropathy that keep millions of people awake at night or hooked on pills. He was born with a rare neurological condition called congenital insensitivity to pain, and for 36 years he has hovered at or near a 1 on the pain scale. He's 5′ 8″, with glasses and thinning brown hair, and he has a road map of scars across his body, mostly hidden beneath a T-shirt bearing the partial crests of Batman, Green Lantern, Flash, and Superman. Because he never learned to avoid injury, which is the one thing pain is really good for, he gets injured a lot. When I ask how many bones he's broken, he lets out a quick laugh.
"Oh gosh. I haven't actually done the count yet," he says. "But somewhere probably around 70 or 80." With each fracture, he didn't feel much of anything—or even notice his injury at all. Whether he saw a doctor depended on how bad the break appeared to be. "A toe or a finger, I'd just take care of that myself," he says, wagging a slightly bent index finger. "Duct tape."
What about something more serious? Pete pauses for a moment and recalls a white Washington day a few years ago. "We had thick snow, and we went inner-tubing down a hill. Well, I did a scorpion, where you take a running start and jump on the tube. You're supposed to land on your stomach, but I hit it at the wrong angle. I face-planted on the hill, and my back legs just went straight up over my head." Pete got up and returned to tubing, and for the next eight months he went on as usual, until he started noticing the movement in his left arm and shoulder felt off. His back felt funny too. He ended up getting an MRI. "The doctor looked at my MRI results, and he was like, 'Have you been in a car accident? About six months ago? Were you skydiving?' "
"I haven't done either," Pete replied.
The doctor stared at his patient in disbelief. "You've got three fractured vertebrae." Pete had broken his back.
Throughout his body today, Pete has a strange feeling: "a weird radiating sensation," as he describes it, an overall discomfort but not quite pain as you and I know it. He and others born with his condition have been compared to superheroes—indomitable, unbreakable. In his basement, where the shelves are lined with videogames about biologically and technologically enhanced soldiers, there is even a framed sketch of a character in full body armor, with the words painless pete. But Pete knows better. "There's no way I could live a normal life right now if I could actually feel pain," he says. He would probably be constrained to a bed or wheelchair from all the damage his body has sustained.
His wife, Jessica, joins us at the café. She is petite and shy, with ice-blue eyes traced in black eyeliner. When I ask her what it's like to live with a man who feels no pain, she sighs. "I worry about him all the time." She worries about him working with his power tools in the basement. She worries about him cooking over a grill. She worries about bigger things too. "If he has a heart attack, he won't be able to feel it," she says. "He'll rub his arm sometimes, and I freak out: 'Are you OK?' " She looks over at Pete, who chuckles. "He thinks it's funny," she says. "I don't think it's funny."
Sunday, April 16, 2017
In the past couple of years, the treatment of chronic pain has undergone an earthshaking transformation as opioid addiction continues to claim — and ruin — lives.
Many primary care doctors no longer liberally prescribe opioid painkillers such as oxycodone, fentanyl and hydrocodone for back pain, migraines and other chronic conditions. Instead, they are increasingly turning to alternative medications and non-drug options such as acupuncture and physical therapy.
"Most primary care doctors are afraid to do pain management because of the opioid backlash," says Michael McClelland, a health care attorney in Rocklin, Calif., and former chief of enforcement for the state Department of Managed Health Care. "Either they don't prescribe anything, and the patient remains in pain, or they turn them over to pain management specialists so someone else is writing that prescription."
As a result, McClelland says, "people in genuine pain are going to find it more difficult to get medicine they may well need."
Thursday, March 30, 2017
This situation did not develop overnight, but it has quickly become one of the biggest public health crises facing America. To understand how and why, I've put together a series of maps and charts that show the key elements of the epidemic — from its start through legalpainkillers prescribed in droves by doctors to the recent rise of the highly potent opioid fentanyl.
Sunday, March 26, 2017
"At least 40 per cent of patients who suffer from severe forms of chronic pain also develop depression at some point, along with other cognitive problems," says Venetia Zachariou of the Icahn School of Medicine at Mount Sinai in New York.
To see if there might be a genetic link between these conditions, Zachariou and her team studied mice with damage to their peripheral nervous system. These mice show symptoms similar to chronic pain in people – they become hypersensitive to harmless touch, and avoid other situations that might also cause them pain.
Until now, pain behaviour in mice had only been studied for at most a week at a time, says Zachariou, whose team monitored their mice for 10 weeks. "At the beginning, we saw only sensory deficits and pain-like symptoms. But several weeks later, the animals developed anxiety and depression-like behaviours."
The team then examined gene activity in three regions in the mouse brains we know are associated with depression and anxiety. Analysing the nucleus accumbens, medial prefrontal cortex, and periaqueductal gray, they found nearly 40 genes where activity was significantly higher or lower than in mice without the nervous system damage.
Sunday, March 19, 2017
In a large representative sample of opioid-naive, cancer-free adults who received a first prescription for opioid pain relievers, the likelihood of long-term opioid use increased with each additional day of medication supplied, starting with the third day, the study team found.
"Knowledge that the risks for chronic opioid use increase with each additional day supplied might help clinicians evaluate their initial opioid prescribing decisions and potentially reduce the risk for long-term opioid use," the authors, led by Bradley Martin, PharmD, PhD, at the University of Arkansas for Medical Sciences in Little Rock, write.
"Discussions with patients about the long-term use of opioids to manage pain should occur early in the opioid prescribing process," they advise in the Morbidity and Mortality Weekly Report of March 17.
Friday, March 03, 2017
Tuesday, February 28, 2017
Scientists are chasing a new lead on a class of drugs that may one day fight both pain and opioid addiction. It's still early days, but researchers report that they've discovered a new small molecule that binds selectively to a long-targeted enzyme, halting its role in pain and addiction while not interfering with enzymes critical to healthy cell function. The newly discovered compound isn't likely to become a medicine any time soon. But it could jumpstart the search for other binders that could do the job.
Pain and addiction have many biochemical roots, which makes it difficult to treat them without affecting other critical functions in cells. Today, the most potent painkillers are opioids, including heroin, oxycodone, and hydrocodone. In addition to interrupting pain, they inhibit enzymes known as adenylyl cyclases (ACs) that convert cells' energy currency, ATP, into a molecule involved in intracellular chemical communication known as cyclic AMP (cAMP). Chronic opioid use can make cells increase the activity of ACs to compensate, causing cAMP levels to skyrocket. When opioid users try to stop using, their cAMP levels remain high, and drugs that reduce those levels—like buprenorphine—have unwanted side effects.
Tuesday, February 14, 2017
On Monday, the American College of Physicians published updated guidelines that say much the same. In making the new recommendations for the treatment of most people with lower back pain, the group is bucking what many doctors do and changing its previous guidelines, which called for medication as first-line therapy.
Dr. Nitin Damle, president of the group's board of regents and a practicing internist, said pills, even over-the-counter pain relievers and anti-inflammatories, should not be the first choice. "We need to look at therapies that are nonpharmacological first," he said. "That is a change."
Sunday, February 05, 2017
Welcome to Pain Researcher, a community forum for anyone involved or interested in the study of pain.
The major purpose of this forum is to facilitate discussion around any and all topics related to the pain research. One important gap that this forum aims to fill involves the sharing of knowledge needed to properly execute pain studies such as detailed protocols, technical tips, tool development, methodological considerations, etc. It is these crucial details that determine the quality and validity of the findings of pain studies, and so we hope that giving a space to discuss such details will improve pain research globally.
Tuesday, January 24, 2017
Wednesday, January 11, 2017
I’ve seen the opioid epidemic as a cop. Living it as a patient has been even worse. - The Washington Post
It was a ruptured disc and related nerve damage. Within a couple of months, it became so severe that I could no longer walk or stand. An MRI later, my surgeon soothingly told me it would all be okay. He would take care of me; the pain would end.
After surgery, I never saw that surgeon again. A nurse practitioner handed me a prescription for painkillers — 180 tablets, 90 each of oxycodone and hydrocodone.
I was lucky: I already knew how easily opioid addiction could destroy a life. I'd arrested addicts and helped people suffering from substance abuse. So as soon as I could, I weaned myself off the medication. Still, I fell into the trap when my pain returned months later, and I started taking the pills again.
Since then, I've been stuck like a growing number of people in a system that leaves patients beholden to terrible health policy, the horrific consequences of federal drug policy, uninformed media hysteria about an opioid epidemic and an army of uncoordinated medical professionals bearing — then seizing — bottles of pills.
I asked repeatedly for alternatives, but I was told none were available. I started physical therapy and sought treatment at an authorized pain management clinic. My first pain management doctor was terse as she prescribed more hydrocodone for daytime and oxycodone for the night, when my pain was worse. To her, I was just another person in a day of people receiving identical treatment. Later she'd say she had little choice: Insurance companies routinely deny even slightly adventurous prescriptions.
A nearby chain pharmacy refused to fill it, saying, "You can't mix hydrocodone and oxycodone." As my prescription testified, I was receiving the required "close monitoring" by a doctor when taking that particular combination. When I called the pain clinic for help, the staff berated me for bothering them. They asked whether I was seeking drugs. I was — the ones they had prescribed.
Friday, January 06, 2017
Public health officials have called the current opioid epidemic the worst drug crisis in American history, killing more than 33,000 people in 2015. Overdose deaths were nearly equal to the number of deaths from car crashes. In 2015, for the first time, deaths from heroin alone surpassed gun homicides.
Tuesday, December 27, 2016
An opioid epidemic is upon us. Prescription painkillers such as fentanyl and morphine can ease terrible pain, but they can also cause addiction and death. The Centers for Disease Control and Prevention estimates that nearly 2 million Americans are abusing or addicted to prescription opiates. Politicians are attempting to stem the tide at state and national levels, with bills to change and monitor how physicians prescribe painkillers and to increase access to addiction treatment programs.
Those efforts may make access to painkillers more difficult for some. But pain comes to everyone eventually, and opioids are one of the best ways to make it go away.
Morphine is the king of pain treatment. "For hundreds of years people have used morphine," says Lakshmi Devi, a pharmacologist at the Ichan School of Medicine Mount Sinai in New York City. "It works, it's a good drug, that's why we want it. The problem is the bad stuff."
Sunday, December 25, 2016
The United States is in the midst of a massive opioid epidemic, as The Washington Post and other news organizations have documented extensively. In 2015, more than 33,000 people died from overdoses of opioids, meaning prescription painkillers, heroin, fentanyl or any combination. That easily keeps pace here with fatal motor vehicle accidents and gun-related deaths.
Certain states have been particularly affected. The Charleston Gazette just reported that opioid wholesalers shipped 780 million oxycodone and hydrocodone pills into West Virginia over a six-year period — enough for 433 pills for every person in the state. Meanwhile, 1,728 West Virginians died from overdoses of those two drugs.
But there's another side to the story. Opioids can be an effective treatment for chronic pain, and too many people around the world have limited access to them.
"We view pain relief as a human rights issue," Kathleen Foley, a neurologist at Memorial Sloan Kettering Cancer Center, said at a Princeton symposium on pain and opioids this month. Historically, she said, pain has been under-treated, and she is concerned that the opioid epidemic "has stigmatized all patients with pain."
Even in this country, some patients may be denied opioids because doctors are not convinced their described pain is real or fear the pills will be diverted to the illegal market. Keith Wailoo, a Princeton historian of medicine and health policy, who also spoke at the symposium, calls it a "pain gap" and says it is why African Americans with sickle cell disease, for example, have reported trouble getting prescription painkillers. "Think of it as a pain gap between the haves and the have-nots, along lines of class and race," Wailoo wrote in the Daily Beast.
Sunday, November 13, 2016
Glia were once thought to simply be passive, supporting cells for neurons. But scientists now know they are involved in everything from metabolism to neurodegeneration. A growing body of evidence points to their key role in pain. In a study published today in Science, researchers at the Medical University of Vienna report that glia are involved in long-term potentiation (LTP), or the strengthening of synapses, in pain pathways in the spinal cord.
Neuroscientists Timothy Bliss and Terje Lømo first described LTP in the hippocampus, a brain area involved in memory, in the 1970s. Since then scientists have been meticulously studying the role this type of synaptic plasticity—the ability of synapses to change in strength—plays in learning and memory. More recently, researchers discovered that LTP could also amplify pain in areas where injuries or inflammation occur. "We sometimes call this a 'memory trace of pain' because the painful insult may lead to subsequent hypersensitivity to painful stimuli, and it was clear that synaptic plasticity can play a role here," says study co-author Jürgen Sandkühler, a neuroscientist also at the Medical University of Vienna. But current models of how LTP works could not explain why discomfort sometimes becomes widespread or experienced in areas a person has never felt it before, he adds.
Saturday, November 12, 2016
Lindley, a neurobiologist, is about to begin the first study ever to directly compare cannabis with an opioid painkiller (in this case, oxycodone) for treating people with chronic pain. She got a grant for this research two years ago, but it has taken that much time to meet all the requirements for working with a drug the federal government still considers highly dangerous.
Before it's given to patients, the marijuana will be kept inside steel narcotics lockers bolted to the wall in a room with surveillance cameras and a combination keypad on the door. Each locker has tamper-proof hinges and requires two keys—each held by a different person. If someone puts the wrong key in one of the locks, it will become inoperable and have to be drilled out.
All this is necessary to comply with rules imposed by the Drug Enforcement Agency to make sure drugs meant for research don't end up on the street, says Heike Newman, a senior regulatory manager at the University of Colorado's Anschutz Medical Campus, where Lindley's study will take place. Newman's job is to help researchers with the paperwork they need to file with various government agencies to get approval for their studies. She says the lockers and renovations to the storage room cost the university about $15,000.
Sunday, November 06, 2016
"These aren't wimps. These people are injecting all sorts of crazy crap into their arms. … But they were finding this excruciating," Hutchinson says. "It just fascinated me." The participants were taking enormous doses of narcotics. How could they experience such exaggerated pain?
The experiment was Hutchinson's first encounter with a perplexing phenomenon called opioid-induced hyperalgesia (OIH). At high doses, opioid painkillers actually seem to amplify pain by changing signaling in the central nervous system, making the body generally more sensitive to painful stimuli. "Just imagine if all the diabetic medications, instead of decreasing blood sugar, increased blood sugar," says Jianren Mao, a physician and pain researcher at Massachusetts General Hospital in Boston who has studied hyperalgesia in rodents and people for more than 20 years.
But how prevalent hyperalgesia is, and whether it plays a role in the U.S. epidemic of opioid abuse and overdose, is unclear. A lack of reliable testing methods and a series of contradictory papers have created believers and skeptics. A few researchers, like Mao, think hyperalgesia is an underappreciated puzzle piece in the opioid epidemic—a force that can pile on pain, drive up doses, and make it harder for chronic users to come off their drugs. Some of those researchers are looking for ways to turn down hyperalgesia, to help patients function on lower doses of their oxycodone, for example, or make it easier to taper off it altogether. Others see OIH as an oddity in the literature—real, and a powerful clue to the workings of pain pathways, but unlikely to tighten the grip of opioids on most patients. Hutchinson thinks the majority of physicians are either unaware of hyperalgesia or unconvinced of its importance. "I think if you surveyed prescribers of opioids, they would be divided probably 60–40."
Thursday, October 27, 2016
But there's a reason your doctor isn't giving you a sugar pill and telling you it's a new wonder drug. The thinking has been that you need to actually believe that you're taking a real drug in order to see any benefits. And a doctor intentionally deceiving a patient is an ethical no-no.
So placebos have pretty much been tossed in the "garbage pail" of clinical practice, says Ted Kaptchuk, director of the Program for Placebo Studies and the Therapeutic Encounter at Beth Israel Deaconess Medical Center. In an attempt to make them more useful, he's been studying whether people might see a benefit from a placebo even if they knew it was a placebo, with no active ingredients. An earlier study found that so-called "open-label" or "honest" placebos improved symptoms among people with irritable bowel syndrome.
And Kaptchuk and his colleagues found the same effect among people with garden-variety lower back pain, the most common kind of pain reported by American adults.
The study included 83 people in Portugal, all of whom had back pain that wasn't caused by cancer, fractures, infections or other serious conditions. All the participants were told that the placebo was an inactive substance containing no medication. They were told that the body can automatically respond to placebos, that a positive attitude can help but isn't necessary and that it was important to take the pills twice a day for the full three weeks.
Wednesday, October 26, 2016
The results "add to a growing body of research showing that animals communicate distress and are affected by the distress of others," says neuroscientist Inbal Ben-Ami Bartal of the University of California, Berkeley.
Neuroscientist Andrey Ryabinin and colleagues didn't set out to study pain transfer. But the researchers noticed something curious during their experiments on mice who were undergoing alcohol withdrawal. Mice in the throes of withdrawal have a higher sensitivity to pokes on the foot. And surprisingly, so did these mice's perfectly healthy cagemates. "We realized that there was some transfer of information about pain" from injured mouse to bystander, says Ryabinin, of Oregon Health & Sciences University in Portland.
When mice suffered from alcohol withdrawal, morphine withdrawal or an inflaming injection, they become more sensitive to a poke in the paw with a thin fiber — a touchy reaction that signals a decreased pain tolerance. Mice that had been housed in the same cage with the mice in pain also grew more sensitive to the poke, Ryabinin and colleagues found. These bystander mice showed other signs of heightened pain sensitivity, such as quickly pulling their tails out of hot water and licking a paw after an irritating shot.
The results are compelling evidence for the social transmission of pain, says neuroscientist Christian Keysers of the Netherlands Institute for Neuroscience in Amsterdam.
Monday, October 24, 2016
How drugs intended for patients ended up in the hands of illegal users: ‘No one was doing their job’ - The Washington Post
The Drug Enforcement Administration targeted these middlemen for a simple reason. If the agency could force the companies to police their own drug shipments, it could keep millions of pills out of the hands of abusers and dealers. That would be much more effective than fighting "diversion" of legal painkillers at each drugstore and pain clinic.
Many companies held back drugs and alerted the DEA to signs of illegal activity, as required by law. But others did not.
Collectively, 13 companies identified by The Washington Post knew or should have known that hundreds of millions of pills were ending up on the black market, according to court records, DEA documents and legal settlements in administrative cases, many of which are being reported here for the first time. Even when they were alerted to suspicious pain clinics or pharmacies by the DEA and their own employees, some distributors ignored the warnings and continued to send drugs.
"Through the whole supply chain, I would venture to say no one was doing their job," said Joseph T. Rannazzisi, former head of the DEA's Office of Diversion Control, who led the effort against distributors from 2005 until shortly before his retirement in 2015. "And because no one was doing their job, it just perpetuated the problem. Corporate America let their profits get in the way of public health."
A review of the DEA's campaign against distributors reveals the extent of the companies' role in the diversion of opioids. It shows how drugs intended for millions of legitimate pain patients ended up feeding illegal users' appetites for prescription narcotics. And it helps explain why there has been little progress in the U.S. opioid epidemic, despite the efforts of public-health and enforcement agencies to stop it.
But there was a time when fentanyl was almost exclusively used by a very small group, and it had nothing to do with Margaret Wente's idea of a "typical drug addict" or poverty or organized crime. What the general public is oblivious to—but the medical community knows—is how fentanyl addiction took its roots in anesthesiology before it made its way into the mainstream.
Dr. Ethan Bryson, associate professor in the anesthesia and psychiatry departments at the Icahn School of Medicine at Mount Sinai, New York, believes it was anesthesiologists who, familiar with fentanyl's pharmacology and abuse potential, first began misusing the opioid.
"If you look at the history of morphine, cocaine, and heroin, these were all drugs which were initially developed for legitimate medical purposes, but subsequently became recreational pharmaceuticals," Bryson told VICE. "They were all experimented on with people with that access. That's well documented in history."
Wednesday, October 19, 2016
When consumed, ghost peppers and other superhots provoke extreme reactions. "Your body thinks it's going to die," as Louisiana pepper grower Ronald Primeaux told the AP in October. "You're not going to die."
But, demonstrated by a rare though severe incident reported recently in the Journal of Emergency Medicine, superhot peppers can cause bodily harm. A 47-year-old man, unnamed in the case study, attempted a super-spicy feat — eating a hamburger served with a ghost pepper puree — and tore a hole in his esophagus.
The root from northern Cameroon had such high levels of a painkiller called tramadol that mice given an extract and placed on a hot plate didn't feel their feet burning at first.
A year later, German rivals came up with a different explanation for the unusual plant. Inexpensive, imported tramadol is so heavily abused in northern Cameroon that it seeps from human and animal waste into the groundwater and soil, where vegetation absorbs it, wrote Michael Spiteller and Souvik Kusari, chemists at the University of Dortmund.
Farmers in Northern Cameroon told the researchers that they take double or triple the safe dosage, and feed tramadol to cattle to help them pull plows through the scorching afternoon sun.
Thursday, October 13, 2016
That statistic has been steadily declining ever since. Today, about 11.5 percent of men between the ages of 24-54 are neither employed nor looking for a job. Economists say that these people are "out of the labor force" — and they don't figure into statistics like the unemployment rate.
This demographic trend has been the subject of much noise and consternation lately. Nicholas Eberstadt, a demographer at the conservative American Enterprise Institute, calls the development a "quiet catastrophe: the collapse, over two generations, of work for American men."
Eberstadt concedes that he can't pinpoint the precise causes, but he implies that the problem, at its root, emanates from some kind of moral or societal dysfunction.
"Time-use surveys suggest [these men] are almost entirely idle," Eberstadt wrote in a Wall Street Journal op-ed a few weeks ago. "Unlike in the past, the U.S. is now evidently rich enough to carry them, after a fashion," he added.
Princeton professor Alan Krueger, a former chief economist at the Department of Labor and former chairman of Obama's Council of Economic Advisers, has taken a look at the same data — but he came away with a different conclusion.
What stood out to him is that a lot of these men say they are in considerable pain.
In a recently released draft of his paper, which he will present at a Federal Reserve conference in Boston on Friday, Krueger finds that 44 percent of male, prime-age labor force dropouts say they took pain medication the day prior — which is more than twice the rate reported by employed men.
Wednesday, October 12, 2016
"It's an amazing result," says Harold Zakon, an evolutionary neurobiologist at the University of Texas, Austin, who was not involved with the work. "This study points us to important areas … that might be targeted to reduce this type of pain."
Naked mole rats are just plain weird. They live almost totally underground in coloniesstructured like honey bee hives, with hundreds of workers servicing a single queen and her few consorts. To survive, they dig kilometers of tunnels in search of large underground tubers for food. It's such a tough life that—to conserve energy—this member of the rodent family gave up regulating its temperature, and they are able to thrive in a low-oxygen, high–carbon dioxide environment that would suffocate or be very painful to humans. "They might as well be from another planet," says Thomas Park, a neuroscientist at the University of Illinois, Chicago.
Gary Lewin, a neuroscientist at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association in Berlin, began working with naked mole rats because a friend in Chicago was finding that the rodent's pain fibers were not the same as other mammals'. In 2008, the studies led to the finding that naked mole rats didn't feel pain when they came into contact with acid and didn't get more sensitive to heat or touch when injured, like we and other mammals do. Lewin was hooked and has been raising the rodents in his lab ever since. They are a little more challenging than rats or mice, he notes, because with just one female per colony producing young, he never really has quite enough individuals for his studies.
So instead of studying the whole animals, he began isolating single nerve cells from the mole rats and investigating them in lab dishes to track the molecular basis of the rodent's pain insensitivity. The pain pathway is kicked off when a substance called nerve growth factor is released by injured or inflamed cells. This factor binds to a protein on the pain-cell surface, a so-called receptor named TrkA, which relays the "pain" message throughout the cell. In us and other mammals, that message increases the activity of a molecular pore, called the TRPV1 ion channel, causing the cell to become more sensitive to touch or heat. "So the cell says 'It hurts more,'" Lewin explains.
But that doesn't happen in naked mole rats. Lewin evaluated the workings of the animal's pain pathway components by mixing them with those of standard rats and putting the combinations in immature frog eggs. For example, the naked mole rat TRPV1 channel sensitized the egg to acid and heat when the rat TrkA was put into the egg cell with it. Thus, Lewin and his colleagues narrowed down the breakdown in this pathway to the TrkA receptor itself. The naked mole rat version of TrkA failed to activate the ion channel as efficiently as the rat version of TrkA, Lewin and his colleagues reveal today in Cell Reports.
Saturday, October 08, 2016
The nature of our old-age ailments has changed in recent years. The study, published this week in The Lancet and conducted by the Institute for Health Metrics and Evaluation at the University of Washington, uses a metric called "Disability Adjusted Life Years." DALYs, as they're abbreviated, combine the number of years of life a person loses if they die prematurely with the amount of time they spend living with a disability. Think of it as time you didn't spend living your #bestlife—because you were sick or dead.
In rich countries, the number one cause of these DALYs is not surprising: ischemic heart disease, which is associated with well-known Western issues like high cholesterol and obesity. But the number two condition is a little strange: plain, old-fashioned, ever-present, low back and neck pain.
Even when you include poor and middle-income countries, low back and neck pain went from ranking 12th as a cause of DALYs globally in 1990 to ranking fourth in 2015, the most recent year. In most countries, it was the leading cause of disability. DALYs from low back and neck pain increased by more than 17 percent from 2005.
The things that make us low-level miserable are now more likely to be simple aches and pains, rather than frightening, communicable diseases like diarrhea. That's encouraging, but it's still a little sad. People all over the world increasingly live long, great lives, only to spend their golden years slathered in IcyHot.
Monday, September 19, 2016
Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse - National Academy of Sciences
Saturday, September 10, 2016
Saturday, September 03, 2016
Saturday, August 20, 2016
Those attempts were doomed to failure because all opioid drugs interact with the brain in the same way. They dock to a specific neural receptor, the mu-opioid receptor, which controls the effects of pleasure, pain relief and need.
Now scientists are trying to create opioid painkillers that give relief from pain without triggering the euphoria, dependence and life-threatening respiratory suppression that causes deadly overdoses.
That wasn't thought possible until 2000, when a scientist named Laura Bohn found out something about a protein called beta-arrestin, which sticks to the opioid receptor when something like morphine activates it. When she gave morphine to mice that couldn't make beta-arrestin, they were still numb to pain, but a lot of the negative side effects of the drug were missing. They didn't build tolerance to the drug. At certain dosages, they had less withdrawal. Their breathing was more regular, and they weren't as constipated as normal mice on morphine.
Before that experiment, scientists thought the mu-opioid receptor was a simple switch that flicked all the effects of opioids on or off together. Now it seems they could be untied. "The hope is you'd have another molecule that looks like morphine and binds to the same receptor, but the way it turns the receptor on is slightly different," says Dr. Aashish Manglik, a researcher at Stanford University School of Medicine who studies opioid receptors.
After Bohn's discovery, a number of people, including a team that includes Manglik, started looking for a drug that could connect to the mu-opioid receptor in a way that avoids the negative effects of beta-arrestin.
To do that, they mapped the receptor's structure in a computer program and started looking for chemicals that would stick to it. "We tried to look for molecules that would still bind to this 3-D structure, but are as far away from morphine and codeine as possible," Manglik says.
The team ran 3 million possibilities through the computer and picked the 23 best candidates to test in a lab. One chemical, PZM21, seems to do what they hoped: Turn the opioid receptor on without using much beta-arrestin. They report their findings in Nature on Wednesday.
Schmidt believes we could learn something from this. By trade, he is an entomologist, an expert on the Hymenoptera order — wasps, bees and ants — but his interest in this insect ritual was not merely academic. He has two teenage boys, and, on this particular morning at least, I found him wondering whether they might benefit from a pain ritual to help introduce them to adulthood.
"I mean, it wouldn't kill them," Schmidt said. "And I think that may be the key to the whole thing: It can't kill you and yet something very real is happening."
It was a bit before 7:30 on a windy weekday morning in Tucson, and Schmidt had just dropped off his 14-year-old at school. At 69, Schmidt has a head of red hair that stubbornly refuses to go gray and a boyish face that glints of mischief. We were driving in his 1999 Toyota Corolla down a road that may have been a desert highway or a city thoroughfare: My East Coast eyes couldn't tell the difference. We pulled up to a traffic light, next to a giant saguaro cactus whose short, upturned arm gave it the look of a crossing guard gesturing us to stop.
Schmidt's new book, "The Sting of the Wild: The Story of the Man Who Got Stung for Science," weaves his theories about stinging insects through a narrative of his personal experiences digging in the dirt. For many readers, the highlight of the book will be the appendix, his celebrated Pain Scale for Stinging Insects, which rates the pain level of dozens of insect stings, an index he created mostly by firsthand experience, either by suffering stings incidentally during field research or, in some cases, by inducing them.
Because stings of the same magnitude don't necessarily feel the same, Schmidt has written haiku-like descriptions for each of the 83 sting entries:
Anthophorid bee, Pain Level 1, "Almost pleasant, a lover just bit your earlobe a little too hard."
Maricopa harvester ant, Level 3, "After eight unrelenting hours of drilling into that ingrown toenail, you find the drill wedged into the toe."
Termite-raiding ant, Level 2, "The debilitating pain of a migraine contained in the tip of your finger."
Club-horned wasp, Level 0.5, "Disappointing. A paper clip falls on your bare foot."
Tuesday, August 09, 2016
Her employer paid for a nerve block that helped temporarily, numbing her lower back, but she could not afford more injections or physical therapy. A decade later, the pain radiates to her right knee and remains largely unaddressed, so deep and searing that on a recent day she sat stiffly on her couch, her curtains drawn, for hours.
The experience of African-Americans, like Ms. Lewis, and other minorities illustrates a problem as persistent as it is complex: Minorities tend to receive less treatment for pain than whites, and suffer more disability as a result.
While an epidemic of prescription opioid abuse has swept across the United States, African-Americans and Hispanics have been affected at much lower rates than whites. Researchers say minority patients use fewer opioids, and they offer a thicket of possible explanations, including a lack of insurance coverage and a greater reluctance among members of minority groups to take opioid painkillers even if they are prescribed. But the researchers have also found evidence of racial bias and stereotyping in recognizing and treating pain among minorities, particularly black patients.
"We've done a good job documenting that these disparities exist," said Salimah Meghani, a pain researcher at the University of Pennsylvania. "We have not done a good job doing something about them."
Wednesday, July 27, 2016
Firefighters arrived and administered oxygen to improve her breathing, but her skin had grown gray and her lips had turned blue. As she lay on the asphalt, the paramedics slipped a needle into her arm and injected another dose of naloxone.
In a moment, her eyes popped open. Her pupils were pinpricks. She was woozy and disoriented, but eventually got her bearings as paramedics put her on a stretcher and whisked her to a hospital.
Every day across the country, hundreds, if not thousands, of people who overdose on opioids are being brought back to life with naloxone. Hailed as a miracle drug by many, it carries no health risk; it cannot be abused and, if given mistakenly to someone who has not overdosed on opioids, does no harm. More likely, it saves a life.
As a virulent opioid epidemic continues to ravage the country, with 78 people in the United States dying of overdoses every day, naloxone's use has increasingly moved out of medical settings, where it has been available since the 1970s, and into the homes and hands of the general public.
But naloxone, also known by the brand name Narcan, has also had unintended consequences. Critics say that it gives drug users a safety net, allowing them to take more risks as they seek higher highs. Indeed, many users overdose more than once, some multiple times, and each time, naloxone brings them back.
Advocates argue that the drug gives people a chance to get into treatment and turn their lives around. And, they say, few addicts knowingly risk needing to be revived, since naloxone ruins their high and can make them violently ill.
Wednesday, July 20, 2016
Eileen Chou, a public policy professor at the University of Virginia, and her collaborators began by analyzing a data set of 33,720 U.S. households and found that those with higher levels of unemployment were more likely to purchase over-the-counter painkillers. Then, using a series of experiments, the team discovered that simply thinking about the prospect of financial insecurity was enough to increase pain. For example, people reported feeling almost double the amount of physical pain in their body after recalling a financially unstable time in their life as compared with those who thought about a secure period. In another experiment, university students who were primed to feel anxious about future employment prospects removed their hand from an ice bucket more quickly (showing less pain tolerance) than those who were not. The researchers also found that economic insecurity reduced people's sense of control, which, in turn, increased feelings of pain.
Chou and her colleagues suggest that because of this link between financial insecurity and decreased pain tolerance, the recent recession may have been a factor in fueling the prescription painkiller epidemic. Other experts are cautious about taking the findings that far. "I think the hypothesis [that financial stress causes pain] has a lot of merit, but it would be helpful to see additional rigorous evidence in a real-world environment," says Heather Schofield, an economist at the University of Pennsylvania who was not involved in the study. Given that stress in general is well known to increase feelings of pain, further research is needed to disentangle financial anxiety from other sources of pressure.
Friday, July 15, 2016
Wednesday, July 06, 2016
Though Pfizer does not sell many opioids compared with other industry leaders, its action sets it apart from companies that have been accused of fueling an epidemic of opioid misuse through aggressive marketing of their products.
Pfizer has agreed to disclose in its promotional material that narcotic painkillers carry serious risk of addiction — even when used properly — and promised not to promote opioids for unapproved, "off-label" uses such as long-term back pain. The company also will acknowledge there is no good research on opioids' effectiveness beyond 12 weeks.
The terms of the agreement were reached with the city of Chicago, which two years ago sued five other opioid manufacturers over alleged misleading marketing of opioids. An announcement of the agreement is expected Wednesday. Pfizer has also been aiding the city's investigation and lawsuit.
Thursday, June 23, 2016
The pills helped ease his pain, but they also caused him to withdraw from his wife, his two children and social life.
"Finally, my wife said, 'You do something about this or we're going to have to make some changes around here,'" said Mr. Scott, 43.
Today, Mr. Scott is no longer taking narcotics and feels better. Shortly after his wife's ultimatum, he entered a local clinic where patients are weaned off opioids and spend up to five weeks going through six hours of training each day in alternative pain management techniques such as physical therapy, relaxation exercises and behavior modification.
Mr. Scott's story highlights one patient's success. Yet it also underscores the difficulties that the Obama administration and public health officials face in reducing the widespread use of painkillers like OxyContin and Percocet. The use and abuse of the drugs has led to a national epidemic of overdose deaths, addiction and poor patient outcomes.
Thursday, June 16, 2016
Sunday, June 12, 2016
Fast relief was a pill away — Percocet, an opioid painkiller — but Dr. Alexis LaPietra did not want to prescribe it. The drug, she explained to Mrs. Pitts, 75, might make her constipated and foggy, and could be addictive. Would Mrs. Pitts be willing to try something different?
Then the doctor massaged Mrs. Pitts's neck, seeking the locus of a muscle spasm, apologizing as the patient groaned with raw, guttural ache and fear.
"Quick prick," said Dr. LaPietra, giving Mrs. Pitts a trigger point injection of Marcaine, a numbing, non-opioid analgesic.
Within seconds, Mrs. Pitts blinked in surprise, her features relaxing, as if the doctor had sponged away her pain lines. She sat up, gingerly moving her head, then beamed and impulsively hugged the doctor, vigorously and with both arms.
Since Jan. 4, St. Joseph's Regional Medical Center's emergency department, one of the country's busiest, has been using opioids only as a last resort. For patients with common types of acute pain — migraines, kidney stones, sciatica, fractures — doctors first try alternative regimens that include nonnarcotic infusions and injections, ultrasound guided nerve blocks, laughing gas, even "energy healing" and a wandering harpist.
Scattered E.R.s around the country have been working to reduce opioids as a first-line treatment, but St. Joe's, as it is known locally, has taken the efforts to a new level.
"St. Joe's is on the leading edge," said Dr. Lewis S. Nelson, a professor of emergency medicine at New York University School of Medicine, who sat on a panel that recommended recent opioid guidelines for the Centers for Disease Control and Prevention. "But that involved a commitment to changing their entire culture."
In doing so, St. Joe's is taking on a challenge that is even more daunting than teaching new protocols to 79 doctors and 150 nurses. It must shake loose a longstanding conviction that opioids are the fastest, most surefire response to pain, an attitude held tightly not only by emergency department personnel, but by patients, too.
Pain is the chief reason nearly 75 percent of patients seek emergency treatment. The E.R. waiting rooms and corridors of St. Joe's, where some 170,000 patients will be seen this year, are frequently pierced by high-pitched cries and anguished moans.
Tuesday, May 31, 2016
There's an unfortunate irony for people who rely on morphine, oxycodone, and other opioid painkillers: The drug that's supposed to offer you relief can actually make you more sensitive to pain over time. That effect, known as hyperalgesia, could render these medications gradually less effective for chronic pain, leading people to rely on higher and higher doses. A new study in rats—the first to look at the interaction between opioids and nerve injury for months after the pain-killing treatment was stopped—paints an especially grim picture. An opioid sets off a chain of immune signals in the spinal cord that amplifies pain rather than dulling it, even after the drug leaves the body, the researchers found. Yet drugs already under development might be able to reverse the effect.
It's no secret that powerful painkillers have a dark side. Overdose deaths from prescription opioids have roughly quadrupled over 2 decades, in near lockstep with increased prescribing. And many researchers see hyperalgesia as a part of that equation—a force that compels people to take more and more medication, while prolonging exposure to sometimes addictive drugs known to dangerously slow breathing at high doses. Separate from their pain-blocking interaction with receptors in the brain, opioids seem to reshape the nervous system to amplify pain signals, even after the original illness or injury subsides. Animals given opioids become more sensitive to pain, and people already taking opioids before a surgery tend to report more pain afterward.
Friday, May 27, 2016
This unsanctioned self-experiment is taking place in the kitchenette of Bautista's University of California, Berkeley, lab. The source of my discomfort is itch powder, the kind anyone can pick up at a novelty store. Its blue packet shows a cartoon man writhing in agony. Below him, in bold letters, are the words, SURPRISE THAT SPECIAL FRIEND! "It's kind of weird people can just buy this stuff on Amazon and not know what it is," Bautista says. A professor of cell and developmental biology, she's pretty sure she knows what the ingredients are: rose-hip hairs and fiberglass. Itchy stuff for sure, but there are far more distressing things in her lab.
Bautista is one of a small but growing number of researchers in the United States trying to decode the molecular secrets of itchiness. She arrived at the specialty the way many others in her field have: by studying pain. For most of medical history, itch and pain were considered variants of the same sensation — itch being just a mild form of pain. What Bautista and others have shown is that while the two share many cellular receptors and molecules, itch has its own biological infrastructure. It's these largely unmapped internal pathways that Bautista has been working to identify for the past seven years.
Wednesday, May 18, 2016
The accompanying article is excerpted from Justin O. Schmidt's new book "The Sting of the Wild: The Story of the Man Who Got Stung for Science," published this spring by John's Hopkins University Press.
Howard Evans, the great naturalist and author of the classic book "Life on a Little Known Planet," was an expert on solitary wasps. Howard, a slight, reserved man with a shock of white hair and a sparkle in his eyes, was especially fond of tarantula hawks. Once, in his dedication to the investigation of these wasps, Howard netted perhaps 10 female tarantula hawks from a flower. He enthusiastically reached into the insect net to retrieve them and, undeterred after the first sting, continued, receiving several more stings, until the pain was so great he lost all of them and crawled into a ditch and just sobbed. Later, he remarked that he was too greedy.
I know of only two people who were "voluntarily" stung by tarantula hawks. I say "voluntarily" as both were performing their duties as part of documentary films, which, among other things, "encouraged" being stung. One was a young, handsome athletic entomologist who knew of the wasps. He deftly reached into the large cylindrical battery jar and grabbed a wasp by the wings. He had her in such a position that her sting harmlessly slid off his thumbnail. We prattled for a minute or so about tarantula hawks while the camera scanned close up to the long sting as it slid harmlessly, missing its mark. Then with a great heave the wasp pulled its abdomen back and thrust the sting under the nail. Yeee…ow (I can't recall if any expressions unsuitable for general audiences were uttered), the wasp was hurled into the air and flew off unharmed. One point for wasp, zero for human.
The other was a solidly built fellow who was apparently a master of performing pain-defying acts of bravery. For the film, I was charged with catching the wasp and delivering it to the scene. Five or six tarantula hawks were easily netted from flowers of an acacia tree; unfortunately, the net snagged on some thorns, and all but one wasp escaped. The remaining wasp appeared to be a male, so I summoned the cameraman to demonstrate how males cannot sting and are harmless. I reached in and casually grabbed "him." At this point, I realized that I was holding a "her." Yeee…ow, except this time it was me. I managed to toss her back in the net, while attempting to explain my blunder and pain on camera. As I was not in the film – perhaps fortunately – the footage was relegated to some obscure studio archive, perhaps someday to be resurrected on YouTube. That episode over, the tarantula hawk was delivered to the rightful actor. He grabbed her, was stung, and showed no reaction beyond a begrudging "Ouch, that did hurt a bit." I figured the guy had no nerves. But his director then handed him a habanero pepper, a tarantula hawk of chili peppers, which he enthusiastically bit into. He became instantly speechless, convinced fire was blasting from his mouth, nose, and ears. Apparently, he did have some nerves — sensitive at least to chili peppers.
How could such a small animal as a tarantula hawk be so memorable? Several years ago I attempted to address this question in a paper entitled "Venom and the Good Life in Tarantula Hawks: How to Eat, Not Be Eaten, and Live Long." The natural history of tarantula hawks provides some insights. Tarantula hawks are the largest members of the spider wasp family Pompilidae, a family some 5,000-species strong that prey solely on spiders. The feature of tarantula hawks that makes them so special is their choice of the largest of all spiders, the fierce and intimidating tarantulas, as their target prey. The old saying "you are what you eat" rings true for tarantula hawks: if you eat the largest spiders, you become the largest spider wasps. As with other spider wasps, the female wasp provides each young with only one spider that serves as breakfast, lunch, and dinner for its entire growing life.